Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (02196) announced that a 2026 first class meeting of H shareholders is scheduled on 27 February 2026 at Sky Fortune Boutique Hotel Shanghai. This meeting will follow the conclusion of the company’s 2026 first extraordinary general meeting and 2026 first class meeting of A shareholders.

The key agenda item is a special resolution regarding the provision of assured entitlements to H shareholders in connection with the proposed spin-off of Fosun Adgenvax (a subsidiary of the company) for listing on the Main Board of the Hong Kong Stock Exchange. According to the announcement, H shareholders intending to attend must lodge their transfer documents by 23 February 2026, with the register for H shares scheduled to close from 24 February to 27 February 2026. The company notes that returning a proxy form does not preclude shareholders from attending and voting in person.

The announcement also outlines procedural information, including the lodging of proxies with the company’s Hong Kong share registrar. Shareholders who attend the meeting in person or by proxy will bear their own travel and accommodation expenses. The notice further clarifies that it is dispatched only to holders of H shares of the company.